News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Rhinomed.
RELATED STOCKHEAD STORIES
Health & Biotech
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health
News
Closing Bell: ASX slips, explorers run hot and a resources play goes parabolic on debut (again)
News
Closing Bell: ASX finishes flat as investors ponder inflation and booster shots
News
ASX Small Cap Lunch Wrap: Who’s opening the door today?
Health & Biotech
Dr Boreham’s Crucible: Testing times for Covid assay developers
Health & Biotech
Australian Clinical Labs flags revenue boost, amid a surge in COVID-19 testing demand
Health & Biotech
ScoPo’s Powerplays: As focus turns to Delta variant, these ASX health stocks are profiting from COVID-19 testing
Health & Biotech
ASX health stocks: Shares in cancer-fighting company Noxopharm edge higher following its full-year results
Health & Biotech
Rhinomed shares gain another 20pc, after 1 million Rhinoswab order from the Victorian government
News
August ASX Winners Column: Reporting season failed to get investors excited, but coal, lithium and COVID battlers did
News
Closing Bell: ASX closes slightly lower, still notches up weekly gain
News
ASX Small Cap Lunch Wrap: Who’s trying not to blink today?
News
10 at 10: These ASX stocks are doing the best amidst the rough markets this morning
Health & Biotech
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
Health & Biotech
ScoPo’s Powerplays: ‘Lots of money on sidelines waiting for pullbacks’, as all eyes are on earnings next week
News
Weekly ASX small cap wrap: Market maintains upward momentum
News